Asploro Journal of Biomedical and Clinical Case Reports

Asploro Journal of Biomedical and Clinical Case Reports

Hiroshi Bando^1,2iD*
1Medical Research/Tokushima University, Tokushima, Japan
²Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan

Corresponding Author: Hiroshi Bando ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 15 July 2024; Accepted date: 29 July 2024; Published date: 05 August 2024

Citation: Bando H. Clinically Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) with Related Factors. Asp Biomed Clin Case Rep. 2024 Aug 05;7(3):201-204.

Copyright © 2024 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Type 2 Diabetes, Glucagon-Like Peptide 1 Receptor Agonists, Oral Hypoglycemic Agent, Proportion of Days Covered, Glucagon-Like Peptide

Abbreviations: T2D: Type 2 Diabetes; GLP-1RA: Glucagon-Like Peptide 1 Receptor Agonists; OHA: Oral Hypoglycemic Agent; PDC: Proportion of Days Covered; GLP-1: Glucagon-Like Peptide

Abstract

Type 2 diabetes (T2D) is a crucial disease, and glucagon-like peptide 1 receptor agonists (GLP-1RA) have become prevalent as effective oral hypoglycemic agents (OHA). GLP-1RA has clinical effects such as improving glucose variability, reducing weight, and decreasing the risk of cardiovascular disease (CVD). However, recent problems include discontinuation, dropout, and incomplete adherence to GLP-1RA. The discontinuation rates of GLP-1RA were 26.2%, 30.8%, and 36.5% at 3, 6, and 12 months, respectively, and increased to 50.3% for obese patients without T2D. Discontinuation was significantly higher for patients with heart failure (odds ratio 1.09) and CVD (1.08), but not for those with CKD (1.03).